Reuters Events | Pharma

Thought leadership and innovation for the Pharmaceutical Industry

Although England accounts for no more than 3% of global pharma sales, it is, alongside Germany, the most externally referenced country in Europe in relation to drug pricing. However, recent structural reforms to the NHS and NICE have complicated an already difficult market access approach.

This exclusive whitepaper aims to simplify these changes and offer you clear guidance on a new model of market access in this crucial European market.